Skip to main content
. 2017 Mar 25;8(45):79175–79187. doi: 10.18632/oncotarget.16577

Figure 1. Waterfall plot (A) and duration on the study (B).

Figure 1

A. Twenty four patients with baseline and subseqent imaging reassessment are shown. Best RECIST response is graphed for each patient. B. All 28 patients are shown in a swmmier plot. Four patients became off-treatment due to rapid clinical progression (n = 3) and toxicity (n = 1) prior to first reassessement scans. Color code defines dose level of treatment with arbitrary patient number assignment. * represents the exceptional responder with ongoing complete response. Dose level 1: olaparib 400mg bid days1-7 with carboplatin AUC3; dose level 2: olaparib 400mg bid days1-7 with carboplatin AUC4; dose level 3: olaparib 400mg bid days1-7 with carboplatin AUC5.